BOSTON, MA—Patients who develop thrombus on the Watchman left atrial appendage (LAA) closure device (Boston Scientific) carry a greater risk of stroke or systemic embolism, and there are hints of a ...

DENVER, CO—Final 5-year data from the PROTECT AF and PREVAIL trials of the Watchman left atrial appendage (LAA) closure device (Boston Scientific) continued to show similar overall stroke prevention ...

MedStar Heart & Vascular Institute now offers patients with irregular heart rhythm a minimally invasive option to reduce the risk of stroke, as well as enable stopping long-term use of blood thinning ...

MedStar Heart & Vascular Institute now offers patients with irregular heart rhythm a minimally invasive option to reduce the risk of stroke, as well as enable stopping long-term use of blood thinning ...

WASHINGTON, DC — New, longer-term data on the Watchman left atrial appendage occluder (Boston Scientific) studied in the PREVAIL trial points to an increased risk of ischemic stroke in ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The newer-generation Watchman device was associated with sustained safety and efficacy out to 2 years when implanted in people at high thromboembolic risk, the PINNACLE FLX IDE study group reported.

CHICAGO – Results from the EWOLUTION registry show that Boston Scientific Corp.'s Watchman Left Atrial Appendage (LAA) Closure device was effective in stroke reduction for patients with non-valvular ...

The Watchman left atrial appendage (LAA) closure device (Boston Scientific) is associated with low 1-year stroke rates, despite being used commercially in older, sicker patients than seen in pivotal ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...